Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications
Cell Communication and Signaling Open Access 26 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).
Akhtar, S. & Maghfoor, I. N. Engl. J. Med. 346, 1830–1831 (2002).
Winter, G. & Harris, W.J. Trends Pharmacol. Sci. 14, 139–143 (2003).
Willett, C.G. et al. Nat Med. 10, 145–147 (2004).
Waldmann, H. Med. Oncol. 19 (Suppl.), S3–S9 (2002).
Hersey, P. Intern. Med. J. 33, 33–43 (2003).
Yee, C. et al. Proc. Natl. Acad. Sci. USA 99, 16168–16173 (2002).
Dudley, M.E. et al. Science 298, 850–854 (2002).
Pardoll, D.M. Nat. Rev. Immunol. 2, 227–238 (2002).
Blattman, J.N. & Greenberg, P.D. Science 305, 200–205 (2004).
Levitsky, H.I. Cancer J. 6 (Suppl.), S281–S290 (2000).
Pardoll, D. Annu. Rev. Immunol. 21, 807–839 (2003).
Chambers, C.A., Kuhns, M.S., Egen, J.G. & Allison, J.P. Annu. Rev. Immunol. 19, 565–594 (2001).
Dong, H. et al. Nat. Med. 8, 793–800 (2002).
Sutmuller, R.P. et al. J. Exp. Med. 194, 823–832 (2001).
Phan, G.Q. et al. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).
Stolberg, S.G. New York Times Magazine 28 Nov (1999) pp. 136–140, 149–150.
Smith, L. & Byers, J.F. JONAS Healthc Law Ethics Regul. 4, 104–110 (2002).
Grilley, B.J. & Gee, A.P. Cytotherapy 5, 197–207 (2003).
Ergenzinger, E. & Spruill, M. Scientist 17, 43 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pardoll, D., Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10, 887–892 (2004). https://doi.org/10.1038/nm0904-887
Issue Date:
DOI: https://doi.org/10.1038/nm0904-887
This article is cited by
-
MAPK signalling-induced phosphorylation and subcellular translocation of PDHE1α promotes tumour immune evasion
Nature Metabolism (2022)
-
Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications
Cell Communication and Signaling (2019)
-
Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective
Journal of Molecular Medicine (2018)
-
Targeted therapies for renal cell carcinoma
Nature Reviews Nephrology (2017)
-
Incorporating Tyrosine Kinase Inhibitors into Treatment Regimens for AML and ALL: Is There a Right or Wrong Way?
Current Hematologic Malignancy Reports (2014)